Literature DB >> 29746819

Continuous thrombin generation in whole blood: New applications for assessing activators and inhibitors of coagulation.

Shannon M Prior1, Kenneth G Mann2, Kalev Freeman3, Saulius Butenas4.   

Abstract

Hemostatic tests have been utilized to clarify the blood coagulation potential. The novel thrombin generation (TG) assay of this study provides explicit information and is the most physiologically-relevant hemostatic test ex vivo. We describe how this assay allows for TG under a number of relevant circumstances. First, whole blood (WB) from healthy individuals was analyzed ± 5 pM tissue factor (TF) and ± contact pathway inhibition. Without an exogenous initiator TG was decreased and delayed, but addition of 5 pM TF shortened the lag phase and increased peak thrombin. Additional experiments included fresh WB from a trauma patient analyzed for endogenous activity and TG from healthy donors subjected to TG antagonists which prolonged the lag phase whereas TG agonists consistently shortened the lag phase in a dose dependent manner. Lastly, platelet-poor plasma was reconstituted with packed red blood cells and TG was monitored in the presence and absence of both TF as an activator and PCPS as a phospholipid surface. Our data illustrate the potential that this continuous TG assay has in the evaluation of disorders relevant to blood coagulation and in the monitoring of treatments administered in response to these disorders.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29746819      PMCID: PMC5993644          DOI: 10.1016/j.ab.2018.05.005

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  44 in total

1.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

2.  Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?

Authors:  Henri M H Spronk; Arne W J H Dielis; Marina Panova-Noeva; René van Oerle; José W P Govers-Riemslag; Karly Hamulyák; Anna Falanga; Hugo Ten Cate
Journal:  Thromb Haemost       Date:  2009-06       Impact factor: 5.249

3.  Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor.

Authors:  R J Baugh; G J Broze; S Krishnaswamy
Journal:  J Biol Chem       Date:  1998-02-20       Impact factor: 5.157

4.  Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation.

Authors:  Matthew F Whelihan; Vicentios Zachary; Thomas Orfeo; Kenneth G Mann
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

5.  The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles.

Authors:  D L Higgins; K G Mann
Journal:  J Biol Chem       Date:  1983-05-25       Impact factor: 5.157

6.  The relation of blood platelets to hemorrhagic disease. By W.W. Duke.

Authors:  W W Duke
Journal:  JAMA       Date:  1983-09-02       Impact factor: 56.272

7.  Questions and answers on prothrombin time standardisation in oral anticoagulant control.

Authors:  E A Loeliger; L Poller; M Samama; J M Thomson; A M Van den Besselaar; J Vermylen; M Verstraete
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

8.  Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events.

Authors:  Anetta Undas; Agnieszka Slowik; Matthew Gissel; Kenneth G Mann; Saulius Butenas
Journal:  Thromb Res       Date:  2011-08-04       Impact factor: 3.944

9.  Activated factor XI and tissue factor in inflammatory bowel disease.

Authors:  A Undas; D Owczarek; M Gissel; K Salapa; K G Mann; S Butenas
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

10.  Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.

Authors:  Joyce Curvers; M Christella L G D Thomassen; Janet Rimmer; Karly Hamulyak; Jan van der Meer; Guido Tans; F Eric Preston; Jan Rosing
Journal:  Thromb Haemost       Date:  2002-07       Impact factor: 5.249

View more
  5 in total

1.  Whole blood thrombin generation is distinct from plasma thrombin generation in healthy volunteers and after severe injury.

Authors:  Julia R Coleman; Ernest E Moore; Jason M Samuels; Joshua J Ryon; Jesse T Nelson; Alexander Olson; Sandi Caus; Matthew G Bartley; Navin G Vigneshwar; Mitchell J Cohen; Anirban Banerjee; Christopher C Silliman; Saulius Butenas
Journal:  Surgery       Date:  2019-09-13       Impact factor: 3.982

2.  Whole Blood Thrombin Generation in Severely Injured Patients Requiring Massive Transfusion.

Authors:  Julia R Coleman; Ernest E Moore; Jason M Samuels; Mitchell J Cohen; Christopher C Silliman; Arsen Ghasabyan; James Chandler; Saulius Butenas
Journal:  J Am Coll Surg       Date:  2021-02-04       Impact factor: 6.532

3.  A novel assay for studying the involvement of blood cells in whole blood thrombin generation.

Authors:  Jun Wan; Joke Konings; Qiuting Yan; Hilde Kelchtermans; Romy Kremers; Bas de Laat; Mark Roest
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

4.  Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.

Authors:  Genmin Lu; Joyce Lin; Khanh Bui; John T Curnutte; Pamela B Conley
Journal:  Res Pract Thromb Haemost       Date:  2020-08-27

Review 5.  Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine.

Authors:  François Depasse; Nikolaus B Binder; Julia Mueller; Thomas Wissel; Stephan Schwers; Matthias Germer; Björn Hermes; Peter L Turecek
Journal:  J Thromb Haemost       Date:  2021-09-26       Impact factor: 16.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.